Beta Bionics (BBNX) reported a Q4 net loss late Tuesday of $2.72 per diluted share.
The company did not provide a year-ago per-share figure.
Analysts polled by Factset expected a loss of $0.90.
Net sales for the quarter ended Dec. 31 were $20.4 million, up from $8.4 million a year earlier.
Analysts surveyed by Factset expected $20.2 million.
The company set full-year 2025 revenue guidance between $80 million and $85 million.
Analysts polled by Factset expect $85.1 million.
Beta Bionics completed its initial public offering on Jan. 30, listing on the Nasdaq Global Market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。